Corporate Finance
Bergs Securities acted as Sole Manager to Observit in its SEK 26 million directed share issue to Eiffel Investment Group
Bergs Securities acted as sole manager and bookrunner to Initiator Pharma Therapeutics in its SEK 56 million rights issue
Corporate Finance
Bergs Securities acted as sole manager and bookrunner to Initiator Pharma Therapeutics in its SEK 56 million rights issue.
Initiator Pharma is a Danish clinical stage emerging pharma company developing innovative drugs that target key unmet medical needs within the central and peripheral nervous system. Initiator Pharma ’s lead project is pudafensine, where the company has reported positive, statistically significant and clinically relevant efficacy data in a Phase IIb clinical trial.
Related News
Corporate Finance
Bergs Securities assisted Smart Eye in the exercise of an incentive program resulting in 497 280 newly issued shares of which around half was divested through a block trade
Corporate Finance
Bergs Securities acted as sole manager and bookrunner to Modus Therapeutics Holding AB in its oversubscribed SEK 28 million rights issue